Stock Analysis
Revolution Medicines, Inc. Common StockRVMD
Sector: Healthcare · Industry: Biological Products, (No Diagnostic Substances)
AnalystsStrong Buy28 analystsPrice is 74% of the way from the year's low to its high.
Cash covers 2107% of debt · FY 2023.
PMP Verdict
Weak fundamentals, expensive
Strengths
- Financial Health75
Risks
- Valuation20
- Growth0
Weak fundamentals at a demanding price.
Market context
-6.0% today· Z 2.5σ· RVMD dropped 6.06% despite positive CHMP opinion for Rasonque, moving 2.51 standard deviations below its 20-day mean.
Bull Case
- ✓Altman Z 11.7 — safe-zone balance sheet
Why is RVMD moving?
ProductRVMD dropped 6.06% despite positive CHMP opinion for Rasonque, moving 2.51 standard deviations below its 20-day mean.
Profile
Strong financial health; growth, profitability, earnings quality, moat and valuation lag behind.
How is each axis scored?
- Valuation20/100 · Weak
- P/E vs own history (n/a)10/25
- FCF yield (-3.2%)0/25
- P/S (3538.3x)0/25
- EV/EBIT (n/a)10/25
- Growth0/100 · Weak
- Revenue CAGR (n/a)0/25
- Net income CAGR (n/a)0/25
- EPS CAGR 5Y (n/a)0/25
- Fwd implied growth (n/a)0/25
- Profitability0/100 · Weak
- ROIC (n/a)0/25
- ROE (-67.8%)0/25
- Net margin (-2833.9%)0/25
- Operating margin (-3145.0%)0/25
- Financial Health75/100 · Strong
- Altman Z (11.73)25/25
- Current ratio (11.38)25/25
- Interest coverage (-15667.3x)0/25
- Net cash / debt (Net cash)25/25
- Quality0/100 · Weak
- Piotroski F (1/9)0/25
- Beneish M (n/a)0/25
- FCF conversion (n/a)0/25
- Margin stability (σ 1046.6%)0/25
- Moat0/100 · Weak
- ROIC >12% years (0/6 yrs)0/25
- Median gross margin (-615.3%)0/25
- FCF-positive years (0/6 yrs)0/25
- Worst-year net margin (worst -3768.3%)0/25
Risk Flags
- ⚠6 loss-making years in recent history
- ⚠Interest coverage -15667.3× — thin debt cushion
About Revolution Medicines, Inc. Common Stock
Revolution Medicines Inc is a clinical-stage precision oncology company developing novel targeted therapies for RAS-addicted cancers. Show more
The Company possesses structure-based drug discovery capabilities built upon chemical biology and cancer pharmacology know-how and proprietary technologies that enable the creation of small molecules tailored to unconventional binding sites. Its research and development pipeline comprises inhibitors that bind directly to RAS variants (RAS(ON) Inhibitors), designed to be used as monotherapy, in combination with other RAS(ON) Inhibitors and/or other therapeutic agents.
Headquarters: REDWOOD CITY, CA · Employees: 883 · Website ↗
Price History
Weekly Candlestick Chart — up to 5Y
Key Metrics
Financial snapshot · Tap any metric for its definition and grade
TTM Snapshot
trailing twelve months · YoYValuation
20EP/E (TTM)—
Price / TTM EPS (own statements)
P/FCF—
Price / Free Cash Flow per share (Finnhub). Inverse of FCF yield — negative when FCF is negative
FCF Yield-3.2%D
Grade D: NegativeTTM (OCF − CapEx) / Market Cap — vs own 5Y history: -15.8%–-2.3% · 85th pct
P/S (TTM)3538.26xD
Grade D: ExpensivePrice / TTM Revenue (own statements)
EV/EBITDA—
Enterprise value / EBITDA (Finnhub) — capital-structure neutral
EV/Sales3557.3xD
Grade D: Very expensiveEnterprise Value / TTM Revenue (Finnhub) — capital-structure neutral sales multiple
Forward P/E—
Price / next-year EPS estimate — shows whether the TTM multiple is rich or just front-loading growth
P/B Ratio14.64xD
Grade D: Very expensivePrice to Book Value. Neg. equity = heavy buybacks
PEG Ratio-0.22A
Grade A: CheapFinnhub PEG — their P/E basis ÷ expected EPS growth. Suppressed when their P/E diverges >2× from our TTM P/E (different basis)
Dividend Yield—
TTM dividend yield (Finnhub) — annual dividends / price. None = no dividend; very high yield can signal distress
Payout Ratio—
Dividends / Net Income (Finnhub) — share of earnings paid out; >90% or negative = unsustainable
Profitability
0EROIC—
NOPAT (EBIT less ~21% tax) / invested capital (equity + debt − cash). Flagship quality metric — durable >15% signals a moat
ROE-67.8%D
Grade D: WeakReturn on Equity. Neg. equity = heavy buybacks
ROA-39.1%D
Grade D: WeakReturn on Assets (Finnhub) — Net Income / Total Assets; how efficiently assets produce profit
Net Margin-2833.9%D
Grade D: LowNet Income / Revenue
Operating Margin—
TTM EBIT / TTM Revenue
Gross Margin—
Gross Profit / Revenue
FCF Margin—
FCF / Revenue
True FCF Margin—
TTM (OCF − CapEx − SBC) / TTM Revenue — SBC treated as a real cost
Growth
0ERevenue CAGR—
Compound annual revenue growth (up to 5Y depending on data availability)
Net Income CAGR—
Compound annual net income growth (up to 5Y depending on data availability)
EPS CAGR (5Y)—
Compound annual EPS growth over up to 5Y of per-share earnings (own statements). Null when either endpoint EPS ≤ 0
Implied EPS Growth—
Analyst forward EPS (normalized basis) vs our GAAP TTM EPS — different bases, so extreme values usually mark cyclically depressed TTM earnings, not real growth
Dilution (5Y)—
Share count change over 5Y
SBC / Net Income—
Stock-based comp/Net income. >30% = dilution risk
SBC / Revenue—
TTM stock-based comp / TTM Revenue
Financial Health
75B+Altman Z-Score11.73A
Grade A: SafeBankruptcy risk. >3 Safe, <1.8 Distress
Current Ratio11.38xA
Grade A: HighCurrent Assets/Liabilities
Quick Ratio11.12xA
Grade A: High(Current Assets − Inventory) / Current Liabilities (Finnhub) — stricter liquidity test, excludes inventory
Interest Coverage-15667.3xD
Grade D: RiskyEBIT/Interest. >10 Strong
Debt RepaymentNet CashA
Grade A: FastYears to repay net debt via FCF
Net Debt/EBIT1.7xA
Grade A: LowLeverage. <2x Low, >4x High
Debt/Equity0.46xA
Grade A: LowDebt / Equity: <1 Conservative, >2 Risky. Not meaningful with non-positive equity; shown as unavailable rather than low debt.
Cash / Debt3.31xA
Grade A: CoveredCash covers how much of total debt. >1 = could repay all debt from cash
Quality
0EPiotroski F-Score1/9D
Grade D: WeakFinancial strength 0–9. >7 Strong
Beneish M-Score—
Earnings manipulation risk. < -2.22 Safe
FCF Conversion—
FCF / Net Income
Margin Stability1046.6%D
Grade D: VolatileEBIT margin std deviation. Lower = stable
Capex / Revenue—
TTM CapEx / TTM Revenue — high % = capital-hungry business
Asset Turnover0.01xD
Grade D: LowRevenue / Total Assets (Finnhub) — how efficiently the asset base generates sales
Insider Transactions
SEC Form 4 · 8 recordsP/S codes are the directional signal; grants, option exercises and tax withholding carry none. Form 4 doesn't flag 10b5-1 plans — scheduled sales may appear within open-market sells.
| Trade date | Insider | Transaction | Shares | Filed |
|---|---|---|---|---|
Sandler Alan B. Filed | Sandler Alan B. | Option exercise | -6000 | |
Sandler Alan B. Filed | Sandler Alan B. | SellOpen market sale | -301 | |
Sandler Alan B. Filed | Sandler Alan B. | SellOpen market sale | -1199 | |
Sandler Alan B. Filed | Sandler Alan B. | SellOpen market sale | -1000 | |
Sandler Alan B. Filed | Sandler Alan B. | SellOpen market sale | -1609 |
Show 3 more filingsShow fewer filings
| Trade date | Insider | Transaction | Shares | Filed |
|---|---|---|---|---|
Sandler Alan B. Filed | Sandler Alan B. | SellOpen market sale | -2200 | |
Sandler Alan B. Filed | Sandler Alan B. | Option exercise | +6.0K | |
Cislini Jeff Filed | Cislini Jeff | SellOpen market sale | -765 |
Option exercise (M) rows report a derivative leg, not an open-market sale — a paired negative entry is the option position being consumed.
More metrics — Moat, Per Share, Balance Sheet, MarketHide additional metrics
Moat
0EROIC >12% Years0/6 yrsD
Grade D: WeakShare of completed fiscal years with ROIC > 12% — measures multi-year capital-return durability
Gross Margin (Med.)-615.3%D
Grade D: WeakMedian annual gross margin across available fiscal years — pricing-power durability
FCF-Positive Years0/6 yrsD
Grade D: WeakShare of completed fiscal years with positive free cash flow
Net Margin Floor-3768.3%D
Grade D: WeakWeakest annual net margin across completed fiscal years — recession/downcycle resilience
Per Share
EPS (TTM)—
TTM net income per share (Finnhub fallback)
Cash / Share$18.38
Cash & short-term investments per share (Finnhub)
Book Value / Share$12.16
Shareholders' equity per share (Finnhub). Negative = accumulated losses / heavy buybacks
Balance Sheet
Total Debt$1.19B
Total debt obligations (short + long term)
Cash & Equiv.$3.94B
Cash and short-term investments
Net Debt$-2.75BA
Grade A: Net CashTotal Debt minus Cash. Negative = Net Cash position
Total Equity$2.61B
Shareholders' equity (book value)
Asset / Liability2.52xA
Grade A: SolidTotal Assets / Total Liabilities
Market
Market Cap$38.15B
Current Market Capitalization
Beta1.42C
Grade C: VolatilePrice sensitivity vs the market (Finnhub) — 1.0 moves with market, >1.2 amplifies swings
How grades work: each metric is graded A–D against fixed thresholds (tap a row for the meaning). Card grades map the pillar score to A+–E — a card grade is that pillar's own score, not an average of the rows shown.
Financials as of Jun 2026 · Ratio snapshot Oct 17, 2026
Key Insights: Revolution Medicines, Inc. Common Stock (RVMD)
RVMD is down 5.97% at the last close — RVMD dropped 6.06% despite positive CHMP opinion for Rasonque, moving 2.51 standard deviations below its 20-day mean.. Revolution Medicines, Inc. Common Stock meets only 1 of 9 Piotroski F-Score criteria — a sign of weak underlying fundamentals. Altman Z-Score of 11.73 sits comfortably in the safe zone (≥ 2.99), indicating low bankruptcy risk. Company is effectively debt-free after netting cash.
- Interest coverage of -15667.3× leaves little room for earnings shocks.
- Revolution Medicines, Inc. Common Stock posted a net loss in 6 of 6 available completed fiscal years (2020–2025).
- At a valuation score of 20/100, RVMD trades at a premium to its historical multiples.
See how RVMD ranks on the Capex Tracker — top 50 capital spenders compared.
Recent Market Moves
See all RVMD moves →| Date | Session | Price | Move | Z-Score |
|---|---|---|---|---|
| Oct 16 | Regular | 176.59 | -6.70% | -2.79 |
| Oct 16 | After-hours | 178.00 | -5.95% | -2.47 |
| Oct 8 | Regular | 188.65 | -6.08% | -3.04 |
| Oct 8 | After-hours | 188.60 | -6.11% | -3.05 |
| Oct 6 | Regular | 198.47 | -4.43% | -2.38 |
Frequently Asked Questions about RVMD
What is the current Revolution Medicines, Inc. Common Stock (RVMD) stock price?
RVMD is trading at $177.96 at the last market close, down 5.97% on the session. PreMarketPrice tracks RVMD pre-market, intraday and after-hours prices.
Is RVMD stock a buy right now?
PreMarketPrice's quantitative model rates Revolution Medicines, Inc. Common Stock's financial health at 75/100. This is a data-driven snapshot of fundamentals, not investment advice.
Is RVMD stock overvalued?
Revolution Medicines, Inc. Common Stock trades at a trailing P/E of n/a and our valuation score rates it 20/100 (higher = cheaper vs. its own history). See the Valuation History and Key Metrics sections for forward P/E, EV/EBITDA and PEG context.
When does Revolution Medicines, Inc. Common Stock report earnings?
No confirmed earnings date is currently scheduled for RVMD. The Earnings section lists recent reports and updates as dates are announced.
What sector does Revolution Medicines, Inc. Common Stock operate in?
Revolution Medicines, Inc. Common Stock operates in the Healthcare sector, within the Biological Products, (No Diagnostic Substances) industry. The Related Stocks section lists sector peers for comparison.
What does Revolution Medicines, Inc. Common Stock do?
Revolution Medicines Inc is a clinical-stage precision oncology company developing novel targeted therapies for RAS-addicted cancers.
About Revolution Medicines, Inc. Common Stock (RVMD) Stock
Revolution Medicines, Inc. Common Stock (RVMD) is a US-listed stock operating in the Healthcare sector, specifically the Biological Products, (No Diagnostic Substances) industry. As of the latest update, Revolution Medicines, Inc. Common Stock is trading at $177.96, down 5.97% on the day with a market capitalization of $38.1 billion. The financial health score for RVMD is 75/100, which indicates excellent financial strength based on profitability, leverage, liquidity, and growth metrics. This page provides real-time pre-market pricing, earnings calendar, financial health analysis, and valuation metrics for RVMD stock.
RVMD Stock Analysis & Key Metrics
On PreMarketPrice, you can track Revolution Medicines, Inc. Common Stock (RVMD) across multiple dimensions:
- Pre-market price & movement: Real-time RVMD stock price with percentage change, updated continuously during pre-market and regular trading hours.
- Valuation & P/E history: Historical P/E, P/S, and P/B ratios for RVMD with trend analysis and normalized valuation multiples.
- Financial statements: Revenue, net income, assets, liabilities, and equity for Revolution Medicines, Inc. Common Stock across multiple reporting periods.
- Financial health score: A composite score of 75/100 based on Altman Z-Score, Piotroski F-Score, profitability, and leverage metrics for RVMD.
- Sector peers: Compare RVMD against 6 other healthcare stocks on key financial metrics.
Is RVMD a Good Stock to Buy?
This page provides data-driven analysis to help you evaluate Revolution Medicines, Inc. Common Stock (RVMD) as an investment. The financial health score of 75/100 suggests excellent financial fundamentals. Valuation metrics show whether the stock is trading above or below its historical average.However, this is not financial advice — always do your own research before investing.
Data on this page is sourced from real-time market feeds, Polygon.io, and Finnhub.Revolution Medicines, Inc. Common Stock (RVMD) trades on NYSE/NASDAQ. Pre-market trading occurs 4:00 AM – 9:30 AM ET. Regular market hours are 9:30 AM – 4:00 PM ET.